Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Respiration. 2017;94(1):62-69. doi: 10.1159/000468545. Epub 2017 Apr 21.
The role of combinations of tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125, 15-3, and 19-9, and CYFRA 21-1 (a fragment of cytokeratin 19) in diagnosing malignant pleural effusion (MPE) has not been clearly established.
This meta-analysis was performed to establish the overall diagnostic accuracies of combinations of these pleural fluid tumor markers for MPE.
The PubMed, Ovid, Embase, Web of Science, and Cochrane bibliographic databases were searched. Sensitivity, specificity, and other measures of the accuracy of combinations of pleural CEA, CA 125, CA 15-3, CA 19-9, and CYFRA 21-1 in the diagnosis of MPE were pooled after a systematic review of English-language studies.
Twenty studies met the inclusion criteria. For pleural fluid tumor marker combinations including more than 3 studies, the summary estimates of the sensitivity/specificity for diagnosing MPE were as follows: CEA + CA 125, 0.65/0.98; CEA + CA 15-3, 0.64/0.98; CEA + CA 19-9, 0.58/0.98; CEA + CYFRA 21-1, 0.82/0.92; and CA 15-3 + CYFRA 21-1, 0.88/0.94.
In patients with undiagnosed pleural effusion, the combinations of positive pleural CEA + CA 15-3 and CEA + CA 19-9 are highly suspicious for pleural malignancy, but the sensitivity of these tests is poor. Therefore, their routine role in the diagnostic algorithm of these patients is questionable, and management decisions should depend on positive cytological or biopsy results from the pleura.
癌胚抗原(CEA)、糖类抗原(CA)125、15-3、19-9 和细胞角蛋白 19 片段(CYFRA 21-1)等肿瘤标志物联合检测在恶性胸腔积液(MPE)诊断中的作用尚未明确。
本研究旨在评估这些胸腔积液肿瘤标志物联合检测在 MPE 诊断中的总体准确性。
通过系统检索 PubMed、Ovid、Embase、Web of Science 和 Cochrane 文献数据库,收集并评估了英文文献中关于胸腔 CEA、CA 125、CA 15-3、CA 19-9 和 CYFRA 21-1 联合检测对 MPE 诊断价值的研究。
共纳入 20 项研究。对于包含 3 项以上研究的肿瘤标志物联合检测,诊断 MPE 的汇总敏感度/特异度分别为:CEA+CA 125,0.65/0.98;CEA+CA 15-3,0.64/0.98;CEA+CA 19-9,0.58/0.98;CEA+CYFRA 21-1,0.82/0.92;CA 15-3+CYFRA 21-1,0.88/0.94。
对于不明原因胸腔积液患者,如果胸腔积液 CEA+CA 15-3 和 CEA+CA 19-9 同时为阳性,则高度怀疑为胸膜恶性肿瘤,但这些检测的敏感度较差。因此,在这些患者的诊断算法中,常规使用这些检测的作用值得质疑,管理决策应取决于胸膜的阳性细胞学或活检结果。